← Leaderboards
Caius Gabriel Radu
University Of California Los Angeles
$8,088,566
Attributed
$17,557,434
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,557,434 · 9
By mechanism
R01$14,929,225 · 7
U54$1,809,608 · 1
P50$818,601 · 1
Top collaborators
- Timothy R Donahue19 shared
- Johannes Czernin11 shared
- Zev A Wainberg7 shared
- Harvey R. Herschman3 shared
- Christine E Mona3 shared
- Nagichettiar Satyamurthy3 shared
- Shahriar Yaghoubi3 shared
- Norbert Pardi2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Timothy R Donahue$4,604,839
- Zev A Wainberg$1,430,425
- Nagichettiar Satyamurthy$357,935
- Shahriar Yaghoubi$1,141,071
- Johannes Czernin$5,995,082
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCellsSignal TransductionPathway InteractionsProductionCancer TherapyMetabolismGeneticResponseMass Spectrum AnalysisSolid NeoplasmNeoplastic CellMalignant Neoplasm Of PancreasPancreatic Ductal AdenocarcinomaImmuneMouse ModelTumor MicroenvironmentClinical TrialsPropertyCombined Modality TherapyResearch PersonnelPositron-Emission TomographyResistance
Grant awards (37)
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer$653,625
R01 · FY2025 · CA
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors$614,124
R01 · FY2025 · CA · contact PI
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$585,317
R01 · FY2025 · CA · contact PI
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC$584,235
R01 · FY2025 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$572,887
R01 · FY2025 · CA
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer$653,452
R01 · FY2024 · CA
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors$628,499
R01 · FY2024 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$575,892
R01 · FY2024 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$567,204
R01 · FY2024 · CA · contact PI
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC$567,087
R01 · FY2024 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$590,100
R01 · FY2023 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$565,439
R01 · FY2023 · CA
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC$528,393
R01 · FY2023 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$48,151
R01 · FY2023 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$607,124
R01 · FY2022 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$602,783
R01 · FY2022 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$96,857
R01 · FY2022 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$634,454
R01 · FY2021 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$630,802
R01 · FY2021 · CA
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$585,018
R01 · FY2018 · CA · contact PI
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$585,018
R01 · FY2017 · CA · contact PI
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$585,018
R01 · FY2016 · CA · contact PI
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$559,454
R01 · FY2015 · CA · contact PI
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$518,617
R01 · FY2014 · CA · contact PI
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy$352,248
U54 · FY2014 · CA · contact PI
Molecular Imaging of DNA Salvage Metabolism in Cancer$219,929
P50 · FY2014 · CA · contact PI
Novel molecular imaging approaches to monitor gene and cell-based therapies$546,171
R01 · FY2013 · CA · contact PI
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy$342,009
U54 · FY2013 · CA · contact PI
Molecular Imaging of DNA Salvage Metabolism in Cancer$205,999
P50 · FY2013 · CA · contact PI
Novel molecular imaging approaches to monitor gene and cell-based therapies$593,141
R01 · FY2012 · CA · contact PI
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy$367,673
U54 · FY2012 · CA · contact PI
Molecular Imaging of DNA Salvage Metabolism in Cancer$116,582
P50 · FY2012 · CA · contact PI
Novel molecular imaging approaches to monitor gene and cell-based therapies$650,363
R01 · FY2011 · CA · contact PI
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy$366,024
U54 · FY2011 · CA · contact PI
Molecular Imaging of DNA Salvage Metabolism in Cancer$122,097
P50 · FY2011 · CA · contact PI
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy$381,654
U54 · FY2010 · CA · contact PI
Molecular Imaging of DNA Salvage Metabolism in Cancer$153,994
P50 · FY2010 · CA · contact PI